Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00548418 · ClinicalTrials.gov registry record · Phase 2
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00548418 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 27 participants.
The verdict
NCT00548418, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the combination of topotecan, cisplatin and bevacizumab is effective in the treatment of recurrent or persistent cervical cancer
Interventions
- DRUG Bevacizumab
- DRUG Cisplatin
- DRUG Topotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2007-02 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00548418
The ClinicalTrials.gov registry entry for NCT00548418 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00548418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00548418 about?
NCT00548418 is a clinical study titled "Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer". The purpose of this study is to determine whether the combination of topotecan, cisplatin and bevacizumab is effective in the treatment of recurrent or persistent cervical cancer
What is the current status of trial NCT00548418?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2007-02. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00548418?
The interventions under investigation include: Bevacizumab (DRUG), Cisplatin (DRUG), Topotecan (DRUG).
Who is sponsoring clinical trial NCT00548418?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.